Wilar Gofarana, Suhandi Cecep, Fukunaga Kohji, Kawahata Ichiro
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.
Heliyon. 2024 Sep 20;10(19):e38229. doi: 10.1016/j.heliyon.2024.e38229. eCollection 2024 Oct 15.
The use of drugs off-label for managing COVID-19 offers a potential approach. Among these potential drugs, tofacitinib, a JAK inhibitor, is strongly implicated in its ability to mitigate mortality by attenuating the cytokine storm syndrome. This study systematically reviewed and quantitatively assessed the effectiveness and safety profile of tofacitinib use through meta-analysis. Through searches of the PubMed, Scopus, and the Cochrane Library databases up to May 31, 2024, six articles meeting inclusion criteria were identified, encompassing 669 patients diagnosed with COVID-19. The review findings indicate that tofacitinib use demonstrates significant clinical efficacy, as evidenced by a reduced risk of mortality (P = 0.003), and a decreased need for invasive mechanical ventilation (P = 0.0002). Furthermore, tofacitinib use is not correlated with an increased risk of adverse drug reactions (P = 0.98), indicating a favorable safety profile. In conclusion, the evidence supports the clinical efficacy of tofacitinib for COVID-19 patients without concomitant risks of adverse effects. Further clinical studies, especially larger-scale randomized controlled trials, are necessary to validate the findings of this study.
使用药物治疗新冠肺炎的非标签用途提供了一种潜在方法。在这些潜在药物中，托法替布（一种JAK抑制剂）因其减轻细胞因子风暴综合征从而降低死亡率的能力而备受关注。本研究通过荟萃分析系统评价并定量评估了托法替布治疗新冠肺炎的有效性和安全性。通过检索截至2024年5月31日的PubMed、Scopus和Cochrane图书馆数据库，共识别出6篇符合纳入标准的文章，涉及669例确诊为新冠肺炎的患者。综述结果表明，使用托法替布具有显著的临床疗效，死亡率风险降低（P = 0.003）以及有创机械通气需求减少（P = 0.0002）可作为证据。此外，使用托法替布与药物不良反应风险增加无关（P = 0.98），表明其安全性良好。总之，现有证据支持托法替布对无不良反应伴随风险的新冠肺炎患者具有临床疗效。需要进一步的临床研究，尤其是大规模随机对照试验，以验证本研究的结果。
